1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Nika Pharmaceuticals Inc.

Nika Pharmaceuticals Inc.

NIKA
Nika Pharmaceuticals Inc.US flagOther OTC
0.20
USD
- -
- -
211.81MMarket Cap
Nika Pharmaceuticals Inc.
NIKA
(Other OTC)

Recent

price

0.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
-0.01
- -
-0.01
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
876
876
876
876
876
1,022
- -
1,038
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
-3
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,040
1,048
1,049
Market Capitalization
301
392
395

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
143.34%
34.53%
Free Cash Flow
- -
75.4%
-48.59%
Net Income, GAAP
- -
4,306.99%
-20.25%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
IDT Australia Limited (IDT.AX)
Alkem Laboratories Limited (ALKEM.NS)
Filament Health Corp. (FH.NE)
H. Lundbeck A/S (HLUBF)
CanaQuest Medical Corp. (CANQF)
N4 Pharma Plc (N4P.L)
Business
Nika Pharmaceuticals Inc (NIKA) develops and distributes pharmaceutical products specializing in treatments for HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, diabetes and diseases requiring strengthened cell immunity; its core offerings include dietary supplements such as Physiolong, Carotilen, Hypocholestin, Biodetoxin, Dry Boza, Fructin, Anthocylen C and Silymaron; antiviral drugs including thymus nuclear glycoprotein (TNG) clinically tested on AIDS patients; six drugs in injection form with two having completed successful clinical trials; four drugs in tablet form; veterinary medicinal products; plant protection products; and generic drugs. The company, founded in 2000 and headquartered in Henderson, Nevada, operates primarily in the United States with distribution agreements targeting Nigeria, Ukraine, UAE, Iraq, Syria and Jordan that project up to €8.5 billion in potential revenue. Recent developments encompass a name change from Centennial Growth Equities Inc in May 2022; a merger with Nika BioTechnology Inc effective March 2024; acquisition of production building and land valued at $2,045,209 plus a vial production line supply agreement in May 2024; purchase of technologies for three generic drugs in tablet form and one dietary supplement in April 2024; a 40% stake in Nika Europe Ltd; and ongoing construction of a GMP-compliant pharmaceutical factory in Europe set for completion by Q1 2026 with production equipment in final testing stages, as updated in December 2025.

Company News

APIChat

  • globenewswire.com

    Nika Pharmaceuticals, Inc. (NIKA) Signed a Consultancy Agreement with MD Global Partners LLC

  • globenewswire.com

    Nika Pharmaceuticals, Inc. (NIKA) Progress Update

  • globenewswire.com

    UPDATE - Nika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June 11th-12th

  • globenewswire.com

    Nika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June 11th-12th

  • globenewswire.com

    Nika Pharmaceuticals, Inc. (NIKA) Markets Analysis and €8.5 Billion Projected Revenue

  • globenewswire.com

    Nika Pharmaceuticals, Inc. (NIKA) Latest Developments

  • globenewswire.com

    Nika Pharmaceuticals, Inc. (NIKA) Signed a Distribution Agreement for Nigeria